Back Back

CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer

The introduction of CDK4/6 inhibitors into the treatment of HR-positive, HER2-negative metastatic breast cancer (mBC) resulted in a paradigm shift, and these agents are now considered the gold standard for first-line treatment. Since their approval, robust real-world data have been collected on the safety and efficacy of these agents outside the confines of a clinical trial. This includes new information on optimal selection between CDK4/6 inhibitors based on patient and disease characteristics and how best to sequence treatments across multiple lines of therapy.

Share

Program Content

Activities

  • Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer
    CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2022

    Expires: August 16, 2023

    View Activity

Faculty

cover img faculity

Megan Kruse, MD

Staff, Breast Medical Oncology, Cleveland Clinic
Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Cleveland, OH

cover img faculity

Ruth O'Regan, MD

Charles A. Dewey Endowed Professor of Medicine
Chair, Department of Medicine, University of Rochester Medical Center
Physician-in-Chief, Strong Memorial Hospital
Associate Director of Education and Mentoring, Wilmot Cancer Institute
Rochester, NY

Provided by

ProCE Banner
ProCE Banner

Jointly provided by PCME and Rockpointe.

Supporters

This program is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation